Methods in Genetics and Clinical Interpretation

Randomized Trial of Personal Genomics for Preventive Cardiology
Design and Challenges

Joshua W. Knowles, MD, PhD; Themistocles L. Assimes, MD, PhD; Michaela Kiernan, PhD; Aleksandra Pavlovic, BS; Benjamin A. Goldstein, PhD; Veronica Yank, MD; Michael V. McConnell, MD; Devin Absher, PhD; Carlos Bustamante, PhD; Euan A. Ashley, MD, DPhil; John P.A. Ioannidis, MD, DSc

Background

Genome-wide association studies (GWAS) have identified more than 1500 disease-associated single nucleotide polymorphisms (SNPs), including many related to atherosclerotic cardiovascular disease (CVD). Associations have been found for most traditional risk factors (TRFs), including lipids, blood pressure/hypertension, weight/body mass index, smoking behavior, and diabetes. GWAS have also identified susceptibility variants for coronary heart disease (CHD). The first and, so far, strongest of these signals was found in the 9p21.3 locus, where common variants in this region increase the relative risk of CVD by 15% to 30% per risk allele in most race/ethnic groups. Subsequent large-scale GWAS meta-analyses and replication studies in largely white/European populations have led to the reliable identification of an additional 26 loci conferring susceptibility to CHD, all with substantially lower effects sizes compared with the 9p21 locus. Many of these CVD susceptibility loci appear to be conferring risk independent of TRFs and thus cannot currently be assessed by surrogate clinical measures.

Among the 27 independent loci identified in the most recent large meta-analyses of CVD, 21 were reported not to be associated with any of the TRFs. The most recent large meta-analyses of CVD, 21 were compared with the 9p21 locus. Many of these CVD susceptibility loci appear to be conferring risk independent of TRFs and thus cannot currently be assessed by surrogate clinical measures (Table 1). Among the 27 independent loci identified in the most recent large meta-analyses of CVD, 21 were reported not to be associated with any of the TRFs.

Several studies have explored whether initial CVD-related genetic markers can improve risk prediction over standard models restricted to TRFs using a genetic risk score (GRS) constructed on the basis of the number of risk alleles inherited. Results to date have been mixed. Although all have shown that a GRS is strongly associated with the outcome of interest independent of TRFs, none were able to demonstrate a significant improvement in the c-statistic. Two of the 3 studies showed some modest improvement in newly defined discrimination indices, including the integrated discrimination index, the net reclassification index, and the clinical net reclassification index (net reclassification index in the intermediate-risk subjects). Thus, the use of these markers has not yet been shown to convincingly outperform models that include TRFs and family history alone.

One important reason for the failure of these markers to demonstrate clinically meaningful improvement of risk prediction relates to the small proportion of the genetic variance explained by these markers, a phenomenon commonly referred to as the heritability gap. The basis for this heritability gap is the focus of intense investigation. Despite this gap, it is still possible that knowledge of genetic risk may improve patient outcomes through means other than enhanced risk reclassification. For instance, genetic testing may improve patient adherence and CVD risk factor reduction for Mendelian disorders related to CHD, such as familial hypercholesterolemia. This effect may be owing to an increase in patient motivation (eg, people who recognize and accept their high risk are more encouraged to reduce it); however, no clinical trial to date has demonstrated that newly discovered genetic markers improve risk factor profiles by improving adherence to prescribed therapy for complex (garden variety) CVD.

Here, we describe the design of an ongoing randomized trial to investigate whether CVD risk factor profiles can be improved by providing participants with knowledge related to their inherited risk of CVD in addition to information on their risk related to measured TRFs. We also discuss some of the challenges that arise in the design and conduct of such a trial and how they were addressed.

Methods

Clinical Trial Registration

This trial is registered at ClinicalTrials.gov (NCT01406808).

Received January 12, 2012; accepted April 4, 2012.

From the Division of Cardiovascular Medicine (J.W.K., T.L.A., A.P., M.V.M., E.A.A.), Stanford Prevention Research Center (M.K., V.Y., J.P.A.I.), Division of General Medical Disciplines (V.Y.), Department of Genetics (C.B.), Department of Health Research and Policy (J.P.A.I.), Stanford University School of Medicine, Stanford, CA; Quantitative Sciences Unit, Stanford University School of Medicine, Palo Alto, CA (B.A.G.); HudsonAlpha Institute for Biotechnology, Huntsville, AL (D.A.); Department of Statistics, Stanford University School of Humanities and Sciences, Stanford, CA (J.P.A.I.).

The online-only Data Supplement is available at http://circgenetics.ahajournals.org/lookup/suppl/doi:10.1161/CIRCGENETICS.112.962746/-/DC1.

Correspondence to Joshua W. Knowles, MD, PhD, Stanford University School of Medicine, Division of Cardiovascular Medicine, Falk CVRC, 500 Pasteur Dr, Stanford, CA 94305. E-mail knowlej@stanford.edu

(Circ Cardiovasc Genet. 2012;5:368-376.)

© 2012 American Heart Association, Inc.

Circ Cardiovasc Genet is available at http://circgenetics.ahajournals.org

DOI: 10.1161/CIRCGENETICS.112.962746

368
Table 1. **SNPs Related to CVD That Are Independent of Traditional Risk Factors**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>rs17465637</td>
<td>C</td>
<td>0.74</td>
<td>1</td>
<td>MA3</td>
<td>1.14</td>
<td>14, 21, 23</td>
</tr>
<tr>
<td>rs99708707</td>
<td>T</td>
<td>0.91</td>
<td>1</td>
<td>PPAP2B</td>
<td>1.17</td>
<td>21</td>
</tr>
<tr>
<td>rs6725887</td>
<td>C</td>
<td>0.15</td>
<td>2</td>
<td>WDR12</td>
<td>1.17</td>
<td>21, 23</td>
</tr>
<tr>
<td>rs2306374</td>
<td>C</td>
<td>0.18</td>
<td>3</td>
<td>MRAS</td>
<td>1.15</td>
<td>21, 22</td>
</tr>
<tr>
<td>rs12190287</td>
<td>G</td>
<td>0.76</td>
<td>6</td>
<td>TCF21</td>
<td>1.08</td>
<td>21</td>
</tr>
<tr>
<td>rs12204265</td>
<td>C</td>
<td>0.67</td>
<td>6</td>
<td>ANKS1A</td>
<td>1.07</td>
<td>21</td>
</tr>
<tr>
<td>rs12526453</td>
<td>C</td>
<td>0.62</td>
<td>6</td>
<td>PHACTR1</td>
<td>1.12</td>
<td>21, 23</td>
</tr>
<tr>
<td>rs11556924</td>
<td>C</td>
<td>0.62</td>
<td>7</td>
<td>ZC3HC1</td>
<td>1.09</td>
<td>21</td>
</tr>
<tr>
<td>rs4977574</td>
<td>G</td>
<td>0.46</td>
<td>9</td>
<td>CDKN2A, CDKN2B</td>
<td>1.28</td>
<td>13, 15, 21, 23</td>
</tr>
<tr>
<td>rs1746048</td>
<td>C</td>
<td>0.87</td>
<td>10</td>
<td>CKX2L2</td>
<td>1.17</td>
<td>14, 21, 23</td>
</tr>
<tr>
<td>rs2246833</td>
<td>C</td>
<td>0.42</td>
<td>10</td>
<td>LIPA</td>
<td>1.09</td>
<td>20</td>
</tr>
<tr>
<td>rs2505083</td>
<td>T</td>
<td>0.37</td>
<td>10</td>
<td>KIAA1462</td>
<td>1.07</td>
<td>20</td>
</tr>
<tr>
<td>rs974819</td>
<td>T</td>
<td>0.29</td>
<td>11</td>
<td>PDGFD</td>
<td>1.07</td>
<td>20</td>
</tr>
<tr>
<td>rs4773144</td>
<td>G</td>
<td>0.44</td>
<td>13</td>
<td>COL4A1, COL4A2</td>
<td>1.07</td>
<td>21</td>
</tr>
<tr>
<td>rs2895811</td>
<td>C</td>
<td>0.43</td>
<td>14</td>
<td>HHIPL1</td>
<td>1.07</td>
<td>21</td>
</tr>
<tr>
<td>rs7176699‡</td>
<td>T</td>
<td>0.56</td>
<td>15</td>
<td>ADAMTS7</td>
<td>1.08</td>
<td>21</td>
</tr>
<tr>
<td>rs12449546‡</td>
<td>C</td>
<td>0.56</td>
<td>17</td>
<td>RASD1, SMCR3, PEMT</td>
<td>1.07</td>
<td>21</td>
</tr>
<tr>
<td>rs143499‡</td>
<td>C</td>
<td>0.36</td>
<td>17</td>
<td>SMG6, SRR</td>
<td>1.07</td>
<td>21</td>
</tr>
<tr>
<td>rs905545‡</td>
<td>A</td>
<td>0.16</td>
<td>21</td>
<td>SLC5A3, MRPS6, KCNE2</td>
<td>1.2</td>
<td>21, 23</td>
</tr>
</tbody>
</table>

SNP indicates single nucleotide polymorphism; CVD, cardiovascular disease; Chrom., chromosome; Ref, reference.

*Odds ratio based on that reported for lead SNP reported by large-scale meta-analyses.\(^{20,21}\)

†Proxy for lead CARDIOGRAM SNP rs17114036 (\(r^2=0.90\)).

‡Proxy for lead CARDIOGRAM SNP rs17609940 (\(r^2=0.91\)).

§Proxy for lead CARDIOGRAM SNP rs3825807 (\(r^2=1\)).

¶Proxy for lead CARDIOGRAM SNP rs12936587 (\(r^2=1\)).

#Proxy for lead CARDIOGRAM SNP rs216172 (\(r^2=1\)).

**Trial Flow**

**Patient Eligibility and Recruitment**

The study population consists of new or continuing patients seen at the Stanford Preventive Cardiology Clinic (PCC), including patients who were referred to the clinic by other providers or patients that self-referred to the clinic. The PCC staff includes 3 attending physicians, a clinical nurse specialist, and a dietician. Flyers describing the trial were sent to cardiologists, general internists, and family physicians at Stanford University Medical Center and in the surrounding area. Inclusion and exclusion criteria are summarized in Table 2. Participants do not receive financial remuneration (or any form of payment) for their participation in the trial.

Patients are eligible if they have a \(\geq 6\%\) risk over the next 10 years or a \(\geq 20\%\) risk over the next 30 years of atherosclerotic CVD as determined by respective Framingham risk scores.\(^{28,29}\) These criteria will result in the inclusion of some individuals who would be classified as low-risk based on current National Cholesterol Education Program/Adult Treatment Panel III guidelines, which define risk as low, moderate, and high, based on cutoffs of \(<10\%, 10\%\) to \(20\%\), and \(>20\%\) over 10 years.\(^{20}\) We chose these eligibility criteria for several reasons. First, we wanted to have fairly broad entry criteria to be able to ascertain whether there is a differential effect of genetic score intervention in these patients, as these patients would be largely left untreated. Interestingly, low risk was defined as \(<6\%\) risk over 10 years until the current National Cholesterol Education Program/Adult Treatment Panel III guidelines were published, and this cut-off is still used as defining the boundary between low and moderate risk in some settings.\(^{31-34}\) Second, we wanted to include low-risk individuals who will not qualify for statin-based therapy.

**Table 2. Eligibility Criteria**

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults age (\geq 18) y</td>
</tr>
<tr>
<td>White/European, South Asian, or Hispanic/Latino race/ethnicity*</td>
</tr>
<tr>
<td>Patient seeking cardiovascular risk evaluation</td>
</tr>
<tr>
<td>At intermediate ((6%) to (20%)) or high risk ((&gt;20%)) over 10 y of CVD, as defined by Framingham 10-y risk score ANB/DR at (\geq 20%) risk of CVD over 30 y using the Framingham 30-y risk calculator</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>History of myocardial infarction, angina, stroke, peripheral arterial disease, PCI, or CABG</td>
</tr>
<tr>
<td>Already on lipid-lowering therapy</td>
</tr>
<tr>
<td>Anticipated survival (&lt;1) y (eg, metastatic cancer)</td>
</tr>
<tr>
<td>Serious conditions that would limit ability to adhere to recommendations (inability to take statins, exercise)</td>
</tr>
<tr>
<td>Already had genetic testing</td>
</tr>
</tbody>
</table>

*The 19 genetic loci that comprise our risk score have been evaluated predominantly in white/European subjects; however, there is considerable overlap in genetic architecture between white/European populations and South Asian or Hispanic/Latino populations. Therefore, we have limited our study population to these 3 race/ethnicity groups.

Y indicates years; CVD, cardiovascular disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft.
primary outcome (change in low-density lipoprotein [LDL] cholesterol). Third, there are persuasive arguments that assessing 30-year or lifetime risk of CVD should be a standard part of risk assessment. This strategy identifies a significant number of individuals (particularly younger individuals) who have a low 10-year risk but a substantial lifetime risk. Targeting these individuals with early, preventive measures to reduce long-term risk could potentially result in substantial public health benefit. Participants are not eligible if they have already had an atherosclerotic-related cardiovascular event, including myocardial infarction, stroke, coronary revascularization of any type, or if they had a CVD risk-equivalent condition such as documented peripheral arterial disease or carotid stenosis. For these participants, we cannot stratify future risk of recurrent events easily, although we know it is high. We also concluded that the life experience related to the initial CVD event(s) experienced by these individuals is likely to serve as a far stronger motivator than any genetic risk score. Patients are also excluded if they were already on lipid-lowering therapy, as the inclusion of participants on different statins at various doses with a range of LDL targets introduces considerable heterogeneity into the analyses. In addition, inclusion of people already adherent to therapy and at goal for risk factor reduction strategies would limit our ability to detect relevant outcomes.

Finally, the SNPs included in the genetic score have been evaluated predominantly in white/European subjects. Because there is considerable overlap in the genetic architecture between white/European populations and South Asian or Hispanic/Latino populations, we thought it reasonable to include these latter race/ethnic groups. In particular the recent publication from the Coronary Artery Disease (C4D) Genetics Consortium demonstrated “little evidence for ancestry-specific effects” of the known CHD/myocardial infarction variants in South Asians versus white/European populations. We are limited by the paucity of published findings in Hispanic populations; however, given the high degree of white/European ancestry in these populations, we would expect these markers to perform well. Furthermore, one of us (J.P.A.L.) has also recently published a manuscript demonstrating that, although the effect sizes for single variants may differ between white/European and Asian populations, they are, on average, larger in 1 or the other ancestry group, thus a multigene signature is likely to carry similar predictive ability, although this is not true for white/European (or Asian) versus African descent. Therefore, we are limiting the trial population to these 3 race/ethnicity groups as based on self-identification, while excluding blacks, East Asians, and Pacific Islanders. We are careful to acknowledge that these SNPs may not convey the exact same risk in South Asian or Hispanic populations in the information we give to patients. (See online-only Data Supplement Appendix.) We evaluated the risk score in blacks and in whites/Europeans from the Atherosclerosis Risk in Communities (ARIC) cohort. In blacks, the relative risk for a standard deviation increase in the Risk Score of CHD over 10 years (controlled for age and sex) is 1.04 (0.93, 1.16), while in whites/Europeans, the equivalent relative risk is 1.18 (1.12, 1.25). This indicates that the SNPs that are used in the risk score are not valid in blacks.

**Initial Clinic Visit: Eligibility and Consent and Guideline-Based Standard Care**

At the initial clinic visit (time=0), eligibility screening and consent are completed (Figure 1). After consent is obtained, participants complete a comprehensive baseline questionnaire. (See online-only Data Supplement Appendix for details.) Participants are then randomized to 1 of the 2 arms using a permuted block algorithm (block size 8) implemented in StudyTrax. A saliva sample is collected for DNA preparation using kits from Oragene, and a medical history and physical examination are also performed. All patients receive standard care including: assessment of personal medical history, social history, and family history; measurements of height, weight, and blood pressure; laboratory testing, such as fasting lipids and blood chemistries; and calculation of 10- and 30-year risk using Framingham models. Most importantly, the patient’s target LDL based on National Cholesterol Education Program/Adult Treatment Panel III guidelines is determined and documented at this initial visit. Based on the same guidelines, recommendations how to optimize one’s diet and physical activity levels are also made. If applicable, medications are prescribed according to guidelines (see Figure 1).

**Second Clinic Visit: Guideline-Based Standard Care and Discussion of Genetic Testing Results With Intervention Patients Only**

The second clinic visit is scheduled 3 months after the initial visit. This schedule follows the usual practice at PCC and was chosen for...
Your Risk Score

Based on the traditional Framingham risk score, your risk of coronary heart disease over the next 10 years is approximately 9.7%.

We tested for a total of 38 possible risk variants or alleles. Out of these 38, you carry 15 variants that are associated with higher risk.

Your genetic profile puts you in the 26th percentile for risk. This means 26% of the general population have a genetic risk score more favorable than you and 74% have a genetic risk score less favorable than you.

Based on the traditional Framingham risk score plus the genetic risk score, your risk of coronary heart disease over the next 10 years is approximately 8.7%.

Figure 2. Genetic risk score report: This score was derived for a hypothetical patient.

several reasons. First, it allows sufficient time to gauge the effectiveness of the initial diet and lifestyle interventions and, when applicable, pharmacological therapy. Second, the interval allows for the completion of genetic testing, which currently takes ~2 months. Immediately before the second clinic visit, participants fill out another study questionnaire and undergo a fasting measurement of lipids. A reassessment of risk factors such as weight, blood pressure, and smoking behavior are performed, to measure progress with initial recommendations. If additional evaluations were completed, such as noninvasive imaging studies of atherosclerotic plaque development (eg, coronary artery calcium scan), these studies are reviewed, as this additional information may change therapeutic recommendations. Guideline-based therapeutic recommendations are discussed with the patient.

At the conclusion of the second clinic visit, the clinician opens a sealed envelope that contains either the genetic risk score or a note indicating that the participant was randomized to the nonintervention arm and will receive his or her genetic risk score at the conclusion of the trial (6-month visit). Importantly, before this point, the clinician is blinded to the results of the genetic testing.

The genetic test results are discussed with the patient by guiding him or her through an individualized genetic risk report (Figure 2). A standard script was developed to help clinicians discuss these results (online-only Data Supplement Appendix). This risk report includes (1) a traditional estimate of both 10-year risks based on the Framingham model; (2) the absolute number of risk alleles carried by the patient (out of a possible 38 alleles); (3) an estimate of the participant’s percentile of genetic risk based on the absolute number of risk alleles in relation to the frequency distribution of risk alleles observed in the ARIC cohort of whites; (4) an estimate of the participant’s 10-year risk of CHD before and after the addition of the genetic data to the standard Framingham 10-year risk model; and (5) a list of SNPs tested annotated with the nearest genes. We also provide participants with a take-home Frequently Asked Questions sheet that reiterates much of the message conveyed by the clinician at the visit (online-only Data Supplement Appendix). We aimed for a very short session (10 minutes) to convey the genetic information. This mode of information delivery does entail the risk that participants may not fully comprehend this information, and this may affect their response to it; however, it would have been difficult to advocate adoption of a genomic information intervention in the everyday busy clinical practice, if this were to take a lot of time to deliver. Moreover, a lengthy delivery of the information may have seriously unbalanced the 2 arms in regards to the attention they received and may have introduced a spurious effect due to greater attention alone. Furthermore, providing more time and detailed emphasis might have given the wrong impression that this information is as important as major genetic risks conferred by major mutations in monogenic disease that require careful and in-depth genetic counseling. This mode of information delivery does entail the risk that participants may not fully comprehend this information, and this may affect their response to it. We do not involve a genetic counselor in the interpretation and discussion of the results of the genetic testing with the participant. Involvement of a genetic counselor would be a different type of intervention, and it would add to the complexity and cost of care. Moreover, it was felt that a genetic counselor would be unnecessary for conveying information for modest multigenetic risks, as opposed to large risks conferred by Mendelian monogenic inheritance. Furthermore, we do not perform a time-matched intervention in the nonintervention arm, since the time required to convey the genetic information is relatively minimal, and time-matching would add an extra layer of complexity to the design.

Third Clinical Visit: Final Outcome Assessment

The third clinical visit is scheduled for 3 months after the second clinic visit (6 months after enrollment at the initial clinic visit). This schedule is typical for PCC and allows adequate assessment of the success of diet, lifestyle, and pharmacological interventions. Participants once again fill out a questionnaire and undergo testing to determine serum lipid levels immediately before this visit. At the clinic visit, the participant’s cardiovascular risk factors are all reassessed, and progress in relation to original therapeutic recommendations is documented and discussed. At this visit, participants in the nonintervention arm also receive their genetic testing results, which are reviewed in the same manner as they were reviewed for the intervention arm at the 3-month visit.

Pharmacological Algorithm for Lowering LDL

A rigid LDL-lowering algorithm is implemented to minimize the possibility of a channeling bias introduced by a treating physician’s knowledge of the genetic testing results. Both the LDL target and the therapeutic regimen are established before the genetic results are disclosed, and no change in the lipid-lowering algorithm is permitted for the duration of the trial except in the case of drug intolerance. If a statin is needed, the initial choice is either simvastatin 20 mg per day for the vast majority of the cases, where mild to moderate (<35%) LDL lowering is required, or atorvastatin 40 mg per day, if more potent LDL lowering (>35%) is required or if there is a previously documented intolerance to simvastatin.

Genotyping Strategy

We encountered several challenges in establishing an efficient method to perform and deliver the genetic testing for this trial. Despite decreasing costs, genetic testing remains relatively expensive if a limited set of SNPs is queried in a small number of individuals (several hundred dollars per participant). In addition, US Food and Drug Administration (FDA)-approved commercial genotyping assays for testing variants associated with complex diseases are not available. Furthermore, we were unable to identify an academic laboratory that offers Clinical Laboratory Improvement Amendments-certified genotyping for these markers, and the cost for developing such an assay at Stanford University Medical Center in 2011 was estimated to be $25,000. Thus, this trial would have not have been possible if it were not for a waiver granted by the Stanford Institutional Review Board allowing us to deliver genetic testing
results to our participants from a non-Clinical Laboratory Improvement Amendments certified laboratory.

We elected to genotype participants in this trial using Illumina’s custom iSelect Cardio-Metabochip (CM), a 200-k array designed by academic investigators in 2009. SNPs included in this array allow for wet-laboratory replication of the top ~2% signals emanating from several large-scale GWAS meta-analyses of cardiovascular-related traits, including body mass index, lipids, blood pressure, and CHD phenotypes and an opportunity to fine map a majority of the currently published validated GWAS loci for CHD. \(^{21}\) Because many investigators around the world were willing to purchase large volumes of the CM array, Illumina made the array available to the scientific community for only ~$40/sample. DNA is purified from saliva samples using standard protocols (PrepIt L2P, Oragene). Genotyping is performed at the HudsonAlpha Institute for Biotechnology using 250 ng of genomic DNA combined with standard Illumina reagents and protocols. Genotype calls are made with Illumina’s GenomeStudio software (http://www.illumina.com), and samples with >98% call rates across all SNPs on the array are considered for analysis. Samples with lower call rates are rerun as necessary.

### Assessment of CHD Risk Using a Genetic Risk Score

At the time this trial was implemented, the published lead SNPs at 21 loci of interest were represented on the CM and were considered in this study. Two loci (located at 17q21.32 and 7q22) identified by the CARDIoGRAM meta-analysis.\(^\text{20,21}\) One may debate whether genetic variants that were not present in the panel that we chose for analysis. Samples with lower call rates are rerun as necessary.

The first set of secondary outcomes includes changes in traditional cardiovascular risk factors other than LDL, such as high-density lipoprotein cholesterol, blood pressure, weight, smoking status, glycemic control (as assessed by hemoglobin A1C), as well as physical activity and dietary patterns. We assess usual leisure time physical activity in the past month with a single self-report item consisting of 6 descriptive categories ranging from inactive to very active.\(^{44}\) This item, the Stanford Leisure-Time Activity Categorical Item (L-Cat), has strong psychometrics in a sample of obese women in a randomized behavioral weight management trial, including excellent test-retest reliability, concurrent criterion validity with pedometer steps and weight loss; and sensitivity to change. To assess usual dietary patterns in the past month, we revised a previously validated brief dietary questionnaire.\(^{45}\) Revisions included updating item content to reflect current CVD-related dietary guidelines and simplifying response categories. The revised questionnaire consists of 11 self-report items, with 10 response categories ranging from one time or less in the last month to 5 plus times a day. We will examine the internal consistency of the dietary items in this sample.

The second set of secondary outcomes involves measures of adherence to, and attitudes toward, taking medications. Medication adherence to cholesterol-lowering drugs and antihypertensive medications are each assessed with a single item using a visual analog scale. These items have adequate validity, with unannounced phone-based pill counts in similar clinical samples.\(^{46}\) Medication attitudes are assessed with 12 self-report items from the Beliefs About Medicines Questionnaire,\(^{47}\) which examine perceived necessity of medications and concerns taking medications as validated against the Illness Perception Questionnaire, the Reported Adherence to Medication scale, and the Sensitive Soma Scale. We will examine the internal consistency of the items in this sample.

The third set of secondary outcomes focuses on perceptions of risk. Relative and absolute perception of risk is each assessed by a single item measured on a 5-point Likert scale ranging from not at all to extremely. The items include: “Over the next 10 years, compared to others your age and sex, how would you rate your risk of having a heart attack or dying due to blocked coronary arteries?” and “Over the next 10 years, how likely do you think it is that you personally will have a heart attack or die due to blocked coronary arteries?”\(^{48}\) These items have validity in other clinical samples.\(^{49}\) We also assess whether patients discuss their risk of CVD with others and encourage others to be screened; each is assessed by a single item measured on a 5-point Likert scale with response options ranging from not at all to extremely. Informed by the transtheoretical stages of change model,\(^{50}\) we assess stages of change with 5 questions adapted from a questionnaire previously validated in a preventive cardiology
setting. These questions focused on stages later than the first (precontemplation) stage, as we reasoned that patients coming to the PCC would have already advanced past the precontemplation stage. We will examine the internal consistency of the items in this sample.

The final set of outcomes focuses on psychological outcomes, given the potential of genetic risk information to have negative psychological impact. Informed by previous literature on the potential psychological impacts of genetic screening for pregnancy and mammogram screening, we assess 5 constructs with single- or 2-question items adapted from previously published reports. To minimize participant burden, we standardize the items using 5-point Likert scales with response options ranging from not at all to extremely. The constructs include anxiety associated with testing, fatalism, depression, stress, and mood. These items have adequate validity in similar clinical samples.

Subgroup Analyses

The size of this trial limits the ability to examine subgroups robustly. We will nevertheless examine trends of association in 2 important subgroups to help plan future intervention trials that build off this pilot study. The first is the subgroup with participants whose 10-year risk of CHD is increased when genetic information is incorporated into the ARIC cohort modeling compared with those who have a lower updated risk. The second is the subgroup that demonstrates a clear reluctance to taking or initiating medications at the 3-month visit based on their responses to the Beliefs about Medicines Questionnaire.

Statistical Methods and Power Calculations

For the primary outcome and all the secondary continuous end points, the mean changes between 3- and 6-month visits will be compared between the 2 arms, adjusting for baseline values. Scales will be analyzed assuming interval scaling. With 50 patients per arm, the trial has ~85% power to detect a difference of 8 mg/dL of LDL cholesterol at α=0.05 (assuming post-treatment LDL values of 108 and 100 mg/dL in the 2 arms and a standard deviation of 15 mg/dL). These LDL values are representative of typical patients in the PCC, with pretreatment LDL cholesterol values ~130 to 160 mg/dL. In general, studies have confirmed a 5% to 15% decrease in LDL with diet and lifestyle changes and a 30% to 40% decrease in LDL with statin therapy. Thus, the trial is well-powered to identify an effect of genetic testing that is in the same range as that of diet and exercise.

Human Subject Protection

The Stanford Institutional Review Board approved this protocol. A research exception was made to allow the return of non-Clinical Laboratory Improvement Amendments certified genotypic information to patients.

Discussion

Genome-wide association studies continue to identify a growing number of susceptibility variants for various complex diseases, offering hope that this information may allow for improved risk prediction and a reduction of risk through the more efficient application of proven primary and secondary prevention strategies; however, the use of these markers in clinical practice has not yet been shown to improve patient outcomes or risk factor profiles in CVD. The National Institutes of Health and the US Preventive Services Task Force has indicated that genetic screening will be highly scrutinized until randomized trials demonstrate clinical benefit. Currently, both the Evaluation of Genomic Applications in Practice and Prevention Working Group and the American College of Cardiology/American Heart Association Taskforce on Practice Guidelines recommend against genetic testing for cardiovascular disease, citing lack of clinical trial data supporting its use. Despite these recommendations and lack of efficacy data, there is growing enthusiasm for personalized medicine approaches, fueled also by direct-to-consumer genetic testing companies. In this context, an important opportunity exists to develop well-designed clinical trials that objectively examine the population effect of providing information on complex trait susceptibility variants to individuals at risk. We seek to help answer some of these questions by determining if genetic testing plus standard care improves cardiovascular risk profiles in the short term compared with standard care alone.

Although there are no published clinical trials using genetic testing specifically for complex CVD, we note the recently reported results of Bloss et al involving over 2000 research volunteers participating in the Scripps Genomic Health Initiative. In this nonrandomized survey, participants reported on changes in levels of anxiety, fat intake, and exercise after being provided the genotyping results of a genome-wide array. The genetic risk score for a number of common conditions was provided to the participants along with genetic counseling services. The investigators found that this information had no effect on exercise and dietary habits. Furthermore, they observed no short-term adverse negative psychological impacts. Importantly, these participants were not enrolled based on a prior existing condition or set of risk factors and so may not represent the effect genetic testing would have on individuals with a specific disease or risk for disease.

Recently, Grant et al published a description of the methods of a randomized trial of genetic risk testing to evaluate risk of diabetes and motivate behavioral change to reduce that risk. The trial design of that study and ours has several similarities, including the creation of a genetic risk score based on the latest set of validated susceptibility variants; enrollment of patients with a baseline elevated risk of a condition; and assessment of secondary outcomes measures, such as changes in weight, exercise, and diet, as well as psychological stages of change, and levels of anxiety. The trials also have important differences. The primary outcome for the Grant et al trial is attendance at 12-week diabetes prevention classes rather than change in a quantitative risk variable (eg, LDL). In addition, the investigators used a novel allocation scheme based on the application of Mendelian randomization to exclude individuals at average genetic risk of diabetes, with the hypothesis that there would be a differential effect of the genetic testing on the behaviors of people at higher versus lower genetic risk. Conversely, we have opted to enroll participants regardless of their genetic profile, but we plan to examine effects between participants whose CVD risk increases because of their genetic profile versus participants whose risk decreases.

Although the CM contains more than 200 000 SNPs related to many cardiometabolic risk factors, participants in this study are receiving genetic risk information restricted to the 19 loci that have been unequivocally associated with CVD and appear to be mediating risk independent of TRFs. We opted for this strategy for several reasons. Although many true susceptibility loci likely exist among the top signals included on the CM, a GRS incorporating many of these loci...
for CVD has not been shown to be superior to a GRS restricted to validated loci. Similarly, the addition of information from either validated or promising susceptibility loci for risk factors of CVD such as LDL, body mass index, or blood pressure to a GRS based on CVD variants alone has also not been shown to improve risk prediction substantially.\textsuperscript{26} Furthermore, we thought it best to focus on a discrete number of susceptibility variants for a single phenotype, given the complexities of conveying the genetic information in a standard clinical visit. Thus, we chose focus on the single phenotype that would be most directly relevant from a clinical perspective and would conceivably have the largest impact on behavior.

Although several trials assessing the efficacy of genetic testing have employed genetic counselors,\textsuperscript{59} we made a conscious decision to avoid that paradigm because we wanted to mimic what might happen in real world scenarios where access to genetic counselors is often limited. Involvement of a genetic counselor would change the purpose of the trial from ascertaining usefulness of genetic testing alone to ascertaining the usefulness of genetic testing combined with genetic counseling. In contrast to Mendelian disorders, where counseling is usually limited to a few family members at risk, counseling for complex genetic disease would involve a much larger population. This approach currently appears neither efficient nor practical, given the number of individuals at intermediate or high risk of CVD.\textsuperscript{61} Optimal ways of conveying complex genetic information to people without necessarily involving genetics experts need to be explored in depth.

We do not perform a time-matched alternate intervention in control patients who do not receive their genetic data at the second visit. Time-matched alternate interventions may be necessary when testing more complex interventions, where considerably more time is spent interacting with volunteers and where there is a danger that this interaction in of itself will result in a benefit that is independent of the intervention being tested. Thus, a time-matched alternate intervention was not deemed necessary, given that the genetic score information can be generally conveyed in 10 minutes and the pharmacological algorithm for lowering LDL is locked for the duration of the trial.

Potential strengths of our trial include the development of a comprehensive risk score based on 19 validated loci associated with CVD independent of TRFs. This risk score was designed to present a fair and balanced view of the genetic risk by showing not only the effect on overall risk but also the patient-specific risk relative to the general population. Another strength is use of change in LDL cholesterol as the primary outcome, which is a quantitative measure that has a direct effect on the risk of CVD and is a widely accepted major target for therapeutic intervention. Many of the secondary outcome measures have also been shown to markedly impact CVD risk, including changes in blood pressure, weight, and diet. We are also capturing information about more subtle but important ways in which genetic testing may have a positive impact, such as moving patients along the spectrum of the stages of change, giving them a more realistic appraisal of their absolute and relative risk of cardiovascular disease. We tried to remove the impact of genetic testing on physician prescriptions, since there is no evidence that physicians should react to such genetic information and allowing such reaction might have added an uncontrolled source of variance (eg, the response might have been better in the genetic information group simply because physicians prescribed higher doses of medication); however, future trials may need to try to address also the impact of such information on physician behavior. Finally, 1 of the key issues we are assessing is whether genetic testing for CVD will result in increased anxiety, depression, or other psychological harm. We chose to address this issue because discussions of the potential for psychological harm are prominent in the screening literature regarding other conditions. For example, the US Preventive Services Task Force has explicitly sought and commented on evidence regarding psychological harms in its evidence reviews of the use of mammography for cancer screening.\textsuperscript{62}

The limitations of the trial include the relatively small sample size and short duration, but these were considered appropriate for a proof of concept trial designed to demonstrate feasibility. We hope that successful completion of the trial will demonstrate that such experimental designs can be adapted to larger, multicenter trials, with long term follow-up that includes hard clinical outcomes. Another potential limitation relates to the generalizability of results, given the patient population being tested. Patients who present to the PCC are likely to be more motivated than the general population and more likely to undertake recommended beneficial lifestyle changes. They also may be more highly educated and more willing to embrace new technologies (as early adopters) compared with the general population. Although we recognize this latter limitation, we also believe that this could be beneficial. If the trial fails to show benefit in a highly motivated population such as this one, it may be more difficult to show benefit in the general population for people who have less interest in seeking expert help and intervention for their cardiovascular health. Furthermore, we will be able to gauge the motivation level within this group in the time between the first and second clinical visits. This should provide us greater insight into the impact of the genetic testing, as we will be able to also use each individual as his or her own control. Lastly, while we have some understanding of the genetic basis for CVD based on large GWAS studies, a large fraction of the inherited risk remains unexplained. In the future, the magnitude of changes in risk imparted by a genetic score may be much greater, and this could significantly affect the patient response and outcome. We are unable to assess whether an enhanced risk score based on additional markers would substantially change the outcome. As more risk variants are discovered, a challenge will be to keep the genetic score up to date. Maintaining an updated genetic risk score is less of a concern for our relatively short-term trial, but it may become an issue for larger long-term trials, where the list of validated or relevant genetic variants may grow substantially during the trial. One option in this situation may be to build an analytic pipeline that can quickly adapt the genetic risk score to include newly validated variants in the risk calculations.
There are similar challenges in the adoption of information also from other cardiovascular biomarkers, including, but not limited to, coronary artery calcium, intima-media thickness, and blood protein biomarkers. Ideally, similar pilot trials should be performed also for other biomarkers that are contemplated for use in clinical practice. Until such trials are available, it is difficult to discern the relative merits of different types of genetic versus nongenetic markers, other than their discriminating ability, which generally seems to be modest for all available proposed markers.

In conclusion, we have designed a trial to assess whether we can reduce risk in patients through providing them with information about CVD susceptibility loci. Trials such as this are necessary before we can advocate for widespread application of genetic testing for common, complex disease phenotypes. This type of trial may be adopted for prevention settings for other chronic diseases in which there are good treatments available but suboptimal risk discrimination that could potentially be improved by consideration of genetic information.

Sources of Funding
The project described in this publication was supported by the Stanford National Institutes of Health/National Center for Research Resources Clinical and Translational Science Awards No. UL1 RR025744. Additional support is through a seed grant from the Stanford University Cardiovascular Institute. Dr Knowles was supported by an American Heart Association, National Fellow-to-Faculty Award, 10FTF3360005.

Disclosures
Dr Ashley is a founder and consultant for Personalis. The other authors report no conflicts.

References


Key Words: personalized medicine ■ coronary artery disease ■ genotyping ■ SNP ■ preventive cardiology
Randomized Trial of Personal Genomics for Preventive Cardiology: Design and Challenges

Joshua W. Knowles, Themistocles L. Assimes, Michaela Kiernan, Aleksandra Pavlovic, Benjamin A. Goldstein, Veronica Yank, Michael V. McConnell, Devin Absher, Carlos Bustamante, Euan A. Ashley and John P.A. Ioannidis

doi: 10.1161/CIRCGENETICS.112.962746

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circgenetics.ahajournals.org/content/5/3/368

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Genetics can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Cardiovascular Genetics is online at:
http://circgenetics.ahajournals.org//subscriptions/